Skip to search formSkip to main contentSkip to account menu

tarenflurbil

Known as: (R)-2-Fluoro-alpha-methyl[1,1'-biphenyl]-4-acetic Acid, R-flurbiprofen 
An orally active synthetic enantiomer of flurbiprofen. Tarenflurbil activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (3)

E-7869MPC-7869flurizan

Broader (1)

Flurbiprofen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
S(+)-Flurbiprofen Shows Potent PGE2 Inhibitory Activity in Inflammatory Cells, Superior Cell Transport Activity and Skin Permeability
We developed a novel topical non-steroidal anti-inflammatory drug (NSAID)patch, S(+)-flurbiprofen plaster, (SFPP), containing S… 
Review
2013
Review
2013
Terapêutica farmacológica na doença de Alzheimer: progressos e esperanças futuras
it is estimated that over 24 million people suffer from dementia worldwide; in Portugal more than 150000 people are affected, and… 
Review
2010
Review
2010
Why so few drugs for Alzheimer's disease? Are methods failing drugs?
Recent studies of Alzheimer's disease (AD) and other neuropsychiatric drug developments raise questions whether failures of some… 
2010
2010
A biobehavioral intervention improved caregiver well-being and some measures of functioning in patients with dementia
Source Citation Gitlin LN, Winter L, Dennis MP, Hodgson N, Hauck WW. A biobehavioral home-based intervention and the well-being… 
2010
2010
In A Large Clinical Trial, Gamma‐Secretase Inhibitor Tarenflurbil is Found Ineffective for Mild Alzheimer Disease
Review
2010
Review
2010
First Trial of a Gamma-Secretase Inhibitor in AD Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease : A Randomized Controlled Trial
Background: It is widely believed that the outcome for patients with psychogenic nonepileptic attacks (pseudoseizures), while… 
Highly Cited
2009
Highly Cited
2009
Why did tarenflurbil fail in Alzheimer's disease?
There has been a lot of disappointment surrounding the recent failure of the largest ever study in patients with Alzheimer's… 
2009
2009
Progress in Alzheimer's disease drug discovery: an update.
While Alzheimer's disease (AD) represents a major healthcare challenge, with 25 to 34 million individuals currently affected… 
2008
2008
Tarenflurbil: a shot on goal
2008
2008
Tarenflurbil slows decline in patients with mild Alzheimer disease
Rofecoxib and valdecoxib have been withdrawn from the market because they increase the risk of cardiovascular events. To… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)